A detailed history of Impax Asset Management Group PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Impax Asset Management Group PLC holds 85,000 shares of NBIX stock, worth $10.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
85,000
Previous 85,000 -0.0%
Holding current value
$10.7 Million
Previous $9.79 Million -0.0%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$114.58 - $153.15 $4.01 Million - $5.36 Million
35,000 Added 70.0%
85,000 $9.79 Million
Q2 2024

Nov 08, 2024

SELL
$130.86 - $143.19 $4.58 Million - $5.01 Million
-35,000 Reduced 41.18%
50,000 $6.88 Million
Q1 2024

Apr 30, 2024

SELL
$130.4 - $143.74 $7.82 Million - $8.62 Million
-60,000 Reduced 54.55%
50,000 $6.9 Million
Q4 2023

Jan 26, 2024

SELL
$106.07 - $132.76 $2.65 Million - $3.32 Million
-25,000 Reduced 18.52%
110,000 $14.5 Million
Q3 2023

Nov 07, 2023

SELL
$94.02 - $117.1 $6.11 Million - $7.61 Million
-65,000 Reduced 32.5%
135,000 $15.2 Million
Q1 2023

May 10, 2023

BUY
$94.11 - $123.02 $2.35 Million - $3.08 Million
25,000 Added 14.29%
200,000 $20.2 Million
Q4 2022

Feb 09, 2023

BUY
$106.72 - $127.06 $2.67 Million - $3.18 Million
25,000 Added 16.67%
175,000 $20.9 Million
Q3 2022

Nov 08, 2022

BUY
$92.03 - $107.81 $13.8 Million - $16.2 Million
150,000 New
150,000 $15.9 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $6.38 Million - $9.78 Million
-75,000 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $5.63 Million - $8.53 Million
75,000 New
75,000 $6.49 Million
Q4 2019

Feb 13, 2020

SELL
$86.8 - $118.57 $1.91 Million - $2.61 Million
-22,000 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $1.84 Million - $2.23 Million
22,000 New
22,000 $1.98 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Impax Asset Management Group PLC Portfolio

Follow Impax Asset Management Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Impax Asset Management Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Impax Asset Management Group PLC with notifications on news.